These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11929349)

  • 41. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
    Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
    Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy.
    Brown RE; Henderson RA; Koster D; Hutton J; Simoons ML
    Eur Heart J; 2002 Jan; 23(1):50-8. PubMed ID: 11741362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of triflusal and acetylsalicylic acid on microthrombi formation in experimental brain ischemia.
    Heye N; Campos A; Kannuki S; Cervós-Navarro J
    Exp Pathol; 1991; 41(1):31-6. PubMed ID: 2022253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
    Matchar DB; Samsa GP; Liu S
    Value Health; 2005; 8(5):572-80. PubMed ID: 16176495
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
    Lancet; 1997 Jun; 349(9066):1641-9. PubMed ID: 9186381
    [TBL] [Abstract][Full Text] [Related]  

  • 47. May aspirin be replaced in the treatment of myocardial infarction?
    Bayés de Luna A
    Eur Heart J; 2000 Mar; 21(6):430-2. PubMed ID: 10681480
    [No Abstract]   [Full Text] [Related]  

  • 48. [Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study].
    Szucs TD; Schwenkglenks M; Berger K; Karsch K
    Z Kardiol; 2003 Mar; 92(3):236-44. PubMed ID: 12658471
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
    Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term cost-effectiveness of clopidogrel in STEMI patients.
    Zhang Z; Kolm P; Mosse F; Jackson J; Zhao L; Weintraub WS
    Int J Cardiol; 2009 Jul; 135(3):353-60. PubMed ID: 18586338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
    Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
    J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Platelet count, antiplatelet therapy and pulmonary embolism--a prospective study in patients with hip surgery.
    Monreal M; Lafoz E; Roca J; Granero X; Soler J; Salazar X; Olazabal A; Bergqvist D
    Thromb Haemost; 1995 Mar; 73(3):380-5. PubMed ID: 7667819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.
    Lamotte M; Annemans L; Evers T; Kubin M
    Pharmacoeconomics; 2006; 24(2):155-69. PubMed ID: 16460136
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis.
    Latour-Pérez J; de Miguel Balsa E; Betegón L; Badia X
    Value Health; 2008; 11(5):853-61. PubMed ID: 18489507
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
    J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
    Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
    Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.
    Lancet; 1997 May; 349(9065):1569-81. PubMed ID: 9174558
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications.
    Hillegass WB; Newman AR; Raco DL
    Pharmacoeconomics; 2001 Jan; 19(1):41-55. PubMed ID: 11252545
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Triflusal in the prevention of vascular dementia].
    López-Pousa S; Mercadal-Dalmau J; Martí-Cuadros AM; Vilalta-Franch J; Lozano-Gallego M
    Rev Neurol; 1997 Oct; 25(146):1525-8. PubMed ID: 9462972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
    BMJ; 1994 Jan; 308(6921):81-106. PubMed ID: 8298418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.